michaelgeist.ca
The Trouble With the TPP, Day 33: Setting the Rules for a Future Pharmacare Program - Michael Geist
Earlier Trouble with the TPP posts focused on the health care implications of the agreement, focusing on patent term extensions, biologics protection, and limits on medical devices and pharma data collection. There is another health-related aspect of the TPP worthy of examination, but it is easy to miss. Chapter 26 of the TPP addresses transparency and anti-corruption, which is not the place you would expect to find provisions with a direct impact on health care. Yet Annex 26-A contains a full section on "transparency and procedural fairness for pharmaceutical products and medical devices." What does this section do? The key aspect is to establish mandatory requirements for a national pharmacare program: